Editor - Betty Law Yuen Kwan | Macau University of Science and T | 24375
E-ISSN: 2314-7326
P-ISSN: 2314-7334

Journal of Neuroinfectious Diseases
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Betty Law Yuen Kwan

Betty Law Yuen Kwan
Betty Law Yuen Kwan
Assistant Professor
Macau University of Science and Technology


Betty Law Yuen Kwan is Assistant Professor in Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau, China.

Research Interest

Molecular and Chemical Biology; Autophagy and neurodegenerative disorders. Educated and obtained Ph.D. degree in The University of Hong Kong. Currently working as an assistant professor in the Macau University of Science and Technology (State Key Laboratory of Quality Research in Chinese Medicines). Research focuses includes the identification of novel autophagic enhancers from Chinese medicinal herbs, for example, the rhizome of Alisma orientale and Radix Polygalae, which may work as a potential therapeutic agent via the induction of autophagic signaling pathway; study on the therapeutic applications of the identified autophagic modulators by using both in vitro and in vivo approaches; identification of novel autophagic enhancers to modulate neurodegenerative disorders through the removal of mutant or mis-folded proteins by autophagy. Research findings published in SCI journals including International Journal of Molecular Sciences (IJMS), Evidence-Based Complementary and Alternative Medicine (ECAM), Cell Death & Diseases, Molecular Cancer Therapeutics, Molecules, Scientific Reports and Oncotarget.